| __timestamp | Intra-Cellular Therapies, Inc. | Sanofi |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 4667000000 |
| Thursday, January 1, 2015 | 87718074 | 5082000000 |
| Friday, January 1, 2016 | 93831530 | 5232000000 |
| Sunday, January 1, 2017 | 79419009 | 5567000000 |
| Monday, January 1, 2018 | 132166913 | 6350000000 |
| Tuesday, January 1, 2019 | 89124838 | 6018000000 |
| Wednesday, January 1, 2020 | 65782137 | 5529000000 |
| Friday, January 1, 2021 | 88845513 | 5692000000 |
| Saturday, January 1, 2022 | 134715000 | 6706000000 |
| Sunday, January 1, 2023 | 180142000 | 6728000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, innovation is the lifeblood of progress. Over the past decade, Sanofi and Intra-Cellular Therapies, Inc. have demonstrated contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Sanofi consistently allocated substantial resources to R&D, with annual expenses peaking at approximately $6.7 billion in 2023. This represents a steady increase of around 44% from 2014. In contrast, Intra-Cellular Therapies, Inc. has shown a more dynamic growth trajectory, with R&D spending surging by over 750% during the same period, reaching $180 million in 2023. While Sanofi's investment dwarfs that of Intra-Cellular Therapies, the latter's rapid growth underscores its commitment to innovation. This comparison highlights the diverse strategies within the pharmaceutical industry, where both scale and growth rate play pivotal roles in shaping the future of healthcare.
Research and Development Investment: Eli Lilly and Company vs Sanofi
Comparing Innovation Spending: AbbVie Inc. and Intra-Cellular Therapies, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Intra-Cellular Therapies, Inc.
Research and Development: Comparing Key Metrics for Amgen Inc. and Intra-Cellular Therapies, Inc.
Comparing Innovation Spending: Sanofi and Sarepta Therapeutics, Inc.
Comparing Innovation Spending: Sanofi and CRISPR Therapeutics AG
Sanofi vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
R&D Spending Showdown: Viatris Inc. vs Intra-Cellular Therapies, Inc.
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs ACADIA Pharmaceuticals Inc.
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Ligand Pharmaceuticals Incorporated
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.